New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 17, 2014
10:25 EDTFLDM, FLDM, ILMN, ILMN, ONT, ONT, PACB, PACB, TMO, TMOLeerink's life science tools analyst holds an analyst/industry conference call
Life Science Tools & Diagnostics Analyst Leonard provides perspectives on new advances in DNA sequencing, particularly Illumina's new sequencing instruments, the HiSeqXTen and NextSeq 500, as well as provide an update on Pacific Biosciences, on an Analyst/Industry conference call to be held on January 17 at 11 am.
News For FLDM;ILMN;ONT;PACB;TMO From The Last 14 Days
Check below for free stories on FLDM;ILMN;ONT;PACB;TMO the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 21, 2014
05:42 EDTILMNIllumina announces strategic partnership with AstraZeneca, Sanofi, Janssen
Illumina (ILMN) announced it has formed collaborative partnerships with leading pharmaceutical companies to develop a universal next-generation sequencing, or NGS,-based oncology test system. The system will be used for clinical trials of targeted cancer therapies with a goal of developing and commercializing a multi-gene panel for therapeutic selection, resulting in a more comprehensive tool for precision medicine. Initial strategic partners include AstraZeneca (AZN), Janssen Biotech, a Johnson & Johnson (JNJ) company, and Sanofi (SNY). Illumina is working with the strategic partners to develop assays that detect and measure multiple variants simultaneously to support partners’ clinical trials, with the objectives of securing regulatory agency approvals and test commercialization. In parallel, Illumina is working with key thought leaders to set standards for NGS-based assays in routine clinical oncology practice, as well as to define regulatory frameworks to enable this new testing paradigm. Together, Illumina and its strategic partners aim to transition from single-analyte companion diagnostics to panel-based assays that select for “companion therapeutics.”
August 20, 2014
10:04 EDTILMNOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
07:18 EDTILMNIllumina upgraded to Outperform from Neutral at Wedbush
Subscribe for More Information
August 19, 2014
11:32 EDTILMNLabCorp prenatal test a negative for Sequenom, says Maxim
Maxim views LabCorp's (LH) announcement today that it will begin offering the informaSeq prenatal test as a long-term negative for Sequenom (SQNM) due to increased competition. The news is also negative for Illumina (ILMN) and PerkinElmer (PKI), who both offer Non-Invasive Prenatal Tests, Maxim adds. The firm recommends buying shares of LabCorp and keeps a Buy rating on the name with a $130 price target.
August 14, 2014
17:16 EDTTMOPaulson & Co gives quarterly update on stakes
Subscribe for More Information
August 12, 2014
10:00 EDTTMO, ILMNOn The Fly: Analyst Initiation Summary
Subscribe for More Information
August 11, 2014
18:07 EDTILMNIllumina initiated with a Buy at Stifel
Target $200.
18:07 EDTTMOThermo Fisher initiated with a Buy at Stifel
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use